This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Illumina (ILMN) Rises on Conclusion of GRAIL Divestment
by Zacks Equity Research
With the divestment now over, we expect Illumina (ILMN) to soar again on the assumption that the company will start to focus on its legacy businesses.
Medtronic (MDT) Shares Positive Data for MiniMed 780G System
by Zacks Equity Research
Medtronic (MDT) presents more compelling data showcasing the benefits of the MiniMed 780G system.
Abbott's (ABT) EPD Expansion Continues Despite FX Headwind
by Zacks Equity Research
Banking on the successful execution of its Branded Generic operating model, Abbott's (ABT) EPD is well-positioned for sustained growth in many of the growing pharmaceutical markets.
Valneva's (VALN) CHIKV Vaccine Gets Health Canada's Approval
by Zacks Equity Research
Valneva's (VALN) IXCHIQ, the world's only licensed chikungunya vaccine, is a critical tool in combating this public health threat.
Best Momentum Stock to Buy for June 24th
by Zacks Equity Research
SCS, BKNIY and RMD made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 24, 2024.
Insulet's (PODD) Omnipod 5 Favored in Study for Type 2 Diabetes
by Zacks Equity Research
Insulet (PODD) reports positive findings from the SECURE-T2D pivotal trial, the largest study of AID therapy in people with type 2 diabetes.
IDEXX (IDXX) Business Faces Macroeconomic Woes, FX Headwinds
by Zacks Equity Research
IDEXX's (IDXX) supply chain operations bear the brunt of geopolitical instability, including the current war in Ukraine.
Quest Diagnostics (DGX) Gains From New M&As Amid Competition
by Zacks Equity Research
In Physician Lab Services, Quest Diagnostics (DGX) is benefiting from the broad-based return to care, overall market growth and share gains driven by the competitive strength of its scale and innovative offerings.
Is It Wise to Hold Bio-Rad (BIO) Stock in Your Portfolio Now?
by Zacks Equity Research
Bio-Rad's (BIO) robust digital PCR business and Clinical Diagnostics segment raise optimism. However, macro issues raise concerns.
Zacks Industry Outlook Highlights Boston Scientific, ResMed, Lantheus and Haemonetics
by Zacks Equity Research
Boston Scientific, ResMed, Lantheus and Haemonetics are part of the Zacks Industry Outlook article.
Thermo Fisher's (TMO) New Buyouts Aid Growth, FX Issues Stay
by Zacks Equity Research
Thermo Fisher's (TMO) business strategy primarily includes expansion through strategic acquisition of technologies and businesses that augment the company's existing products and services.
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Boston Scientific (BSX) to Buy Silk Road, Boost Cardiology
by Zacks Equity Research
This acquisition is expected to enhance Boston Scientific's (BSX) market position and revenue streams in North America and Europe.
QIAGEN's (QGEN) New QCI Interpret Release Enhances AI Functions
by Zacks Equity Research
QIAGEN's (QGEN) latest QCI Interpret release improves the performance of high-throughput NGS labs.
4 Medical Product Stocks to Buy From a Recovering Industry
by Indrajit Bandyopadhyay
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. BSX, RMD, LNTH and HAE are well-poised to gain from the favorable factors.
Quest Diagnostics' (DGX) New Buyout Ramps Up Cancer Diagnosis
by Zacks Equity Research
Quest Diagnostics (DGX) completes the acquisition of PathAI Diagnostics, accelerating the adoption of AI and digital pathology to improve cancer diagnosis.
Charles River (CRL) Advances in T-Cell Therapy With New Alliance
by Zacks Equity Research
Charles River (CRL) and Captain T Cell announced an agreement on plasmid DNA and retrovirus vector production program for the treatment of patients having solid tumor.
QIAGEN (QGEN) Debuts dPCR Microbial DNA Detection Assays
by Zacks Equity Research
QIAGEN (QGEN) launches new QIAcuity dPCR assays for microbial applications, enhancing infectious disease research and surveillance.
STERIS (STE) Gains From New Offerings, Macro Issues Ail
by Zacks Equity Research
STERIS' (STE) AST successfully offers a wide range of sterilization modalities through a worldwide network of more than 50 contract sterilization and laboratory facilities.
Is Mind Medicine MindMed (MNMD) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Mind Medicine (MindMed) Inc. (MNMD) and ResMed (RMD) have performed compared to their sector so far this year.
BrainsWay (BWAY) to Advance in DEEP TMS for MDD With New Trial
by Zacks Equity Research
BrainsWay (BWAY) emphasizes the potential of the accelerated protocol, citing previous data suggesting comparable outcomes with traditional, longer protocols.
Zimmer Biomet (ZBH) Advances in GenAI Technology With RevelAi
by Zacks Equity Research
Zimmer Biomet (ZBH) and RevelAi Health have joined forces to solve social and clinician problems by commercializing RevelAi's patient care-management platform and care team dashboard for providers.
Thermo Fisher's (TMO) New Launch Supports Full Lab Automation
by Zacks Equity Research
Thermo Fisher's (TMO) first-of-its-kind innovation for CO2 incubators supports emerging automated cell therapy production processes.
Zimmer Biomet (ZBH) to Broaden Knee Surgery Line With New Alliance
by Zacks Equity Research
Zimmer Biomet (ZBH) joins forces with Think Surgical for the distribution of customized TMINI - Miniature Robotic System in the U.S. market.
Haemonetics (HAE) Banks on Growing Plasma Arm, Innovation
by Zacks Equity Research
Haemonetics (HAE) is gaining from the newly completed limited market release of the new Express Plus technology with more than 60,000 real-world collections.